mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1.

Published

Journal Article

Colorectal cancers harboring KRAS or BRAF mutations are refractory to current targeted therapies. Using data from a high-throughput drug screen, we have developed a novel therapeutic strategy that targets the apoptotic machinery using the BCL-2 family inhibitor ABT-263 (navitoclax) in combination with a TORC1/2 inhibitor, AZD8055. This combination leads to efficient apoptosis specifically in KRAS- and BRAF-mutant but not wild-type (WT) colorectal cancer cells. This specific susceptibility results from TORC1/2 inhibition leading to suppression of MCL-1 expression in mutant, but not WT, colorectal cancers, leading to abrogation of BIM/MCL-1 complexes. This combination strategy leads to tumor regressions in both KRAS-mutant colorectal cancer xenograft and genetically engineered mouse models of colorectal cancer, but not in the corresponding KRAS-WT colorectal cancer models. These data suggest that the combination of BCL-2/BCL-XL inhibitors with TORC1/2 inhibitors constitutes a promising targeted therapy strategy to treat these recalcitrant cancers.

Full Text

Duke Authors

Cited Authors

  • Faber, AC; Coffee, EM; Costa, C; Dastur, A; Ebi, H; Hata, AN; Yeo, AT; Edelman, EJ; Song, Y; Tam, AT; Boisvert, JL; Milano, RJ; Roper, J; Kodack, DP; Jain, RK; Corcoran, RB; Rivera, MN; Ramaswamy, S; Hung, KE; Benes, CH; Engelman, JA

Published Date

  • January 2014

Published In

Volume / Issue

  • 4 / 1

Start / End Page

  • 42 - 52

PubMed ID

  • 24163374

Pubmed Central ID

  • 24163374

Electronic International Standard Serial Number (EISSN)

  • 2159-8290

Digital Object Identifier (DOI)

  • 10.1158/2159-8290.CD-13-0315

Language

  • eng

Conference Location

  • United States